Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: A prospective study

Bone

Volumn 48, Issue 3, 2011, Pages 571-577

  te Winkel, M L ^a   de Muinck Keizer Schrama, S M P F ^a   de Jonge, R ^b   van Beek, R D ^a   van der Sluis, I M ^a   Hop, W C J ^b   Pieters, R ^a   van den Heuvel Eibrink, M M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Bone density; Childhood cancer; Homocysteine; Methionine synthase reductase; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; GENOMIC DNA; HOMOCYSTEINE; METHIONINE SYNTHASE REDUCTASE; VITAMIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE DENSITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; FEMALE; FOLATE METABOLISM; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; MALE; OSTEOLYSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BONE DENSITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FERREDOXIN-NADP REDUCTASE; FOLIC ACID; FRACTURES, BONE; GENOTYPE; GERM CELLS; HOMOCYSTEINE; HUMANS; INFANT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VITAMIN B 12;

EID: 79751524496     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.10.163     Document Type: Article

References (37)

1. Arikoski P., Komulainen J., Riikonen P., Voutilainen R., Knip M., Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab 1999, 84:3174-3181.
2. Vassilopoulou-Sellin R., Ramirez I. Severe osteopenia and vertebral compression fractures after complete remission in an adolescent with acute leukemia. Am J Hematol 1992, 39:142-143.
3. Boot A.M., Van den Heuvel-Eibrink M.M., Hählen K., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Bone mineral density in acute lymphoblastic leukemia. Eur J Cancer 1999, 35:1693-1697.
4. van der Sluis I.M., van den Heuvel-Eibrink M.M., Hahlen K., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Altered bone mineral density and body composition and fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 2002, 141:204-210.
5. Halton J.M., Atkinson S.A., Fraher L., Webber C., Gill G.J., Dawson S., et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996, 11:1774-1783.
6. Crofton P.M., Ahmed S.F., Wade J.C., Stephen R., Elmlinger M.W., Ranke M.B., et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998, 83:3121-3129.
7. Reid I.R. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 1997, 137:209-217.
8. Ragab A.H., Frech R.S., Vietti T.J. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970, 25:580-585.
9. Riancho J.A., Valero C., Zarrabeitia M.T. MTHFR polymorphism and bone mineral density: meta-analysis of published studies. Calcif Tissue Int 2006, 79:289-293.
10. Levasseur R. Bone tissue and hyperhomocysteinemia. Joint Bone Spine 2009, 76:234-240.
11. Harris E.D., Sjoerdsma A. Collagen profile in various clinical conditions. Lancet 1966, 2:707-711.
12. Kang A.H., Trelstad R.L. A collagen defect in homocystinuria. J Clin Invest 1973, 52:2571-2578.
13. Lubec B., Fang-Kircher S., Lubec T., Blom H.J., Boers G.H. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996, 1315:159-162.
14. Gjesdal C.G., Vollset S.E., Ueland P.M., Refsum H., Drevon C.A., Gjessing H.K., et al. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med 2006, 166:88-94.
15. van Meurs J.B., Dhonukshe-Rutten R.A., Pluijm S.M., van der Klift M., de Jonge R., Lindemans J., et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004, 350:2033-2041.
16. McLean R.R., Jacques P.F., Selhub J., Tucker K.L., Samelson E.J., Broe K.E., et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004, 350:2042-2049.
17. Weisberg I., Tran P., Christensen B., Sibani S., Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
18. Krajinovic M., Lamothe S., Labuda D., Lemieux-Blanchard E., Theoret Y., Moghrabi A., et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004, 103:252-257.
19. Vaughn J.D., Bailey L.B., Shelnutt K.P., Dunwoody K.M., Maneval D.R., Davis S.R., et al. Methionine synthase reductase 66A→G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C→T variant. J Nutr 2004, 134:2985-2990.
20. Steer C.D., Emmett P.M., Lewis S.J., Smith G.D., Tobias J.H. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with spinal BMD in 9-year-old children. J Bone Miner Res 2009, 24:117-124.
21. Broxson E.H., Stork L.C., Allen R.H., Stabler S.P., Kolhouse J.F. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989, 49:5879-5883.
22. Refsum H., Wesenberg F., Ueland P.M. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991, 51:828-835.
23. Veerman A.J., Kamps W.A., van den Berg H., van den Berg E., Bokkerink J.P., Bruin M.C., et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009, 10:957-966.
24. van der Sluis I.M., de Muinck Keizer-Schrama S.M., Krenning E.P., Pols H.A., Uitterlinden A.G. Vitamin D receptor gene polymorphism predicts height and bone size, rather than bone density in children and young adults. Calcif Tissue Int 2003, 73:332-338.
25. Fredriks A.M., van Buuren S., Burgmeijer R.J., Meulmeester J.F., Beuker R.J., Brugman E., et al. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000, 47:316-323.
26. Fredriks A.M., van Buuren S., Wit J.M., Verloove-Vanhorick S.P. Body index measurements in 1996-7 compared with 1980. Arch Dis Child 2000, 82:107-112.
27. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
28. Johnson J., Dawson-Hughes B. Precision and stability of dual-energy X-ray absorptiometry measurements. Calcif Tissue Int 1991, 49:174-178.
29. Kroger H., Vainio P., Nieminen J., Kotaniemi A. Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone 1995, 17:157-159.
30. van der Sluis I.M., de Ridder M.A., Boot A.M., Krenning E.P., de Muinck Keizer-Schrama S.M. Reference data for bone density and body composition measured with dual energy X-ray absorptiometry in white children and young adults. Arch Dis Child 2002, 87:341-347. discussion 341-7.
31. Tanner J.M., Whitehouse R.H. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976, 51:170-179.
32. Bathum L., Von Bornemann Hjelmborg J., Christiansen L., Madsen J.S., Skytthe A., Christensen K. Evidence for an association of methylene tetrahydrofolate reductase polymorphism C677T and an increased risk of fractures: results from a population-based Danish twin study. Osteoporos Int 2004, 15:659-664.
33. Abrahamsen B., Madsen J.S., Tofteng C.L., Stilgren L., Bladbjerg E.M., Kristensen S.R., et al. A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. J Bone Miner Res 2003, 18:723-729.
34. Jackson R.C. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther 1984, 25:61-82.
35. Baram J., Allegra C.J., Fine R.L., Chabner B.A. Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 1987, 79:692-697.
36. Ruud E., Holmstrom H., Brosstad F., Wesenberg F. Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis. Scand J Clin Lab Invest 2006, 66:67-78.
37. Jones T.S., Kaste S.C., Liu W., Cheng C., Yang W., Tantisira K.G., et al. CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. J Clin Oncol 2008, 26:3031-3037.